Dr. Yuyan Wang 王玉艳
Chief Physician, Associate Professor
Medical Oncology (II), Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized, individualized, and multidisciplinary treatment for thoracic tumors, primarily advanced lung cancer, thymic tumors, and pleural mesothelioma.
Dr. Wang earned a clinical doctorate in internal medicine from Peking University in 2007. Since then, Dr. Wang has worked in the Department of Thoracic Medical Oncology at Peking University Cancer Hospital, becoming Chief Physician in 2018. Dr. Wang completed postdoctoral oncology research at the University of Maryland (2013–2015) and was a visiting scholar at Johns Hopkins University School of Medicine (2019–2020).
Professional roles
- Standing Committee Member, Lung Cancer Professional Committee, Beijing Anti-Cancer Association
- Standing Committee Member, Lung Cancer Youth Committee, Beijing Medical Reward Foundation; Deputy Leader, Internal Medicine Group and Palliative Rehabilitation Group
- Member, Geriatric Oncology Professional Committee (CGOS), China Gerontology Society
- Member, Tumor Science Popularization Professional Committee, Medical Science Popularization Branch, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Wang Yuyan). Papers usually list the name as Yuyan Wang or Wang Y.
Selected publications
71 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Chin Med J (Engl), 2026 (senior author): Immune-related adverse events between elderly patients with gastrointestinal and lung cancers: A real-world study. PubMed 41942399
- Thorac Cancer, 2024 (senior author): Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival. PubMed 38923348
- Ann Transl Med, 2021 (first author): Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. PubMed 33553326
- Front Oncol, 2020 (first author): Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. PubMed 32391280
- Mol Ther Nucleic Acids, 2017 (first author): A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma. PubMed 28325293
- Zhonghua Jie He He Hu Xi Za Zhi, 2015 (first author): [Prognostic factors and response of chemotherapy including amrubicin in small cell lung cancer patients]. PubMed 26268231
- Zhonghua Jie He He Hu Xi Za Zhi, 2013 (first author): [Prognosis related clinical and molecular factors in malignant pleural mesothelioma]. PubMed 23856136
- Zhongguo Fei Ai Za Zhi, 2011 (first author): [Primary lung cancer with gastrointestinal metastasis: 2 case report and literature review]. PubMed 21426674
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion